切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2021, Vol. 10 ›› Issue (06) : 591 -598. doi: 10.3877/cma.j.issn.2095-3224.2021.06.005

论著

进展期结直肠癌患者根治术后行预防性腹腔热灌注化疗的安全性评价
林曜1, 郭熙恺1, 沈楚1, 李源1, 王点石1, 胡鹏1, 王征1, 吴轲1, 吴川清1,(), 陶凯雄1,()   
  1. 1. 430022 武汉,华中科技大学同济医学院附属协和医院胃肠外科
  • 收稿日期:2021-07-20 出版日期:2021-12-25
  • 通信作者: 吴川清, 陶凯雄
  • 基金资助:
    国家自然科学基金(81600401,81874184)

Safety evaluation of preventive intraperitoneal hyperthermic perfusion chemotherapy in patients with advanced colorectal cancer after radical resection

Yao Lin1, Xikai Guo1, Chu Shen1, Yuan Li1, Dianshi Wang1, Peng Hu1, Zheng Wang1, Ke Wu1, Chuanqing Wu1,(), Kaixiong Tao1,()   

  1. 1. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
  • Received:2021-07-20 Published:2021-12-25
  • Corresponding author: Chuanqing Wu, Kaixiong Tao
引用本文:

林曜, 郭熙恺, 沈楚, 李源, 王点石, 胡鹏, 王征, 吴轲, 吴川清, 陶凯雄. 进展期结直肠癌患者根治术后行预防性腹腔热灌注化疗的安全性评价[J/OL]. 中华结直肠疾病电子杂志, 2021, 10(06): 591-598.

Yao Lin, Xikai Guo, Chu Shen, Yuan Li, Dianshi Wang, Peng Hu, Zheng Wang, Ke Wu, Chuanqing Wu, Kaixiong Tao. Safety evaluation of preventive intraperitoneal hyperthermic perfusion chemotherapy in patients with advanced colorectal cancer after radical resection[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(06): 591-598.

目的

本研究旨在探讨进展期结直肠癌患者根治术后行腹腔内灌注化疗(HIPEC)预防腹膜转移的围手术期安全性。

方法

本研究回顾性分析了2020年1月至2021年2月于华中科技大学同济医学院附属协和医院胃肠外科123例行根治手术+HIPEC治疗的局部进展期结直肠癌患者的病例资料。并按美国卫生及公共卫生部公布的常见不良事件评价标准(CTCAE 5.0)对进展期结直肠癌患者围手术期安全性进行评价。通过logistics模型分析局部进展期结直肠癌患者不良事件发生的独立危险因素。

结果

123例患者均行根治术+HIPEC。共有45例(36.6%)进展期结直肠癌患者术后发生2级及以上不良事件。患者术后平均住院时间为(11.7±4.30)天。对行1~3次HIPEC患者的不良事件发生率进行差异分析结果表明Ⅱ度骨髓抑制发生率差异有统计学意义(χ2=7.303,P=0.012)。经过单因素及多因素logistics分析,结果表明女性(OR=3.280,95%CI:1.355~7.939,P=0.007)是局部进展期结直肠癌患者根治术后行HIPEC治疗的不良事件发生的独立危险因素,18.5 kg/m2≤BMI≤24.0 kg/m2OR=0.155,95%CI:0.041~0.587;P=0.011)则属于独立保护因素。

结论

进展期结直肠癌患者根治术后行HIPEC并没有显著增加常见术后并发症的发生率,但围手术期行3次HIPEC的进展期结直肠癌患者Ⅱ度骨髓抑制显著高于行1次或2次。同时,临床医师应密切关注女性或BMI过低(或过高)的进展期结直肠癌患者根治术后行HIPEC治疗时的不良事件发生率。

Objective

This study aimed to explore the perioperative safety of radical resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment and prevention of peritoneal metastasis in patients with advanced colorectal cancer.

Methods

This study retrospectively analyzed 123 patients with radical surgery + HIPEC locally advanced colorectal cancer in the Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2020 to February 2021. The perioperative safety of patients with advanced colorectal cancer was evaluated according to common terminology criteria for adverse events (CTCAE 5.0) published by the US Department of Public Health. We analyzed the independent risk factors of adverse events in patients with locally advanced colorectal cancer through the logistics model.

Results

All 123 patients underwent radical resection + HIPEC treatment. A total of 45 cases (36.6%) of advanced colorectal cancer patients had adverse events of grade 2 and above after surgery. The average postoperative hospital stay was (11.7±4.30) days. The difference analysis of the incidence of adverse events in patients undergoing 1~3 times of HIPEC showed that there was a significant difference in the incidence of gradeⅡbone marrow suppression (χ2=7.303, P=0.012). Univariate and multivariate logistics analysis showed that women (OR=3.280, 95%CI: 1.355~7.939, P=0.007) was an independent risk factor for adverse events in locally advanced colorectal cancer patients treated with HIPEC after radical surgery, while 18.5 kg/m2≤BMI≤24.0 kg/m2 was an independent protective factor (OR=0.155, 95%CI: 0.041~0.587, P=0.011).

Conclusion

Radical surgery combined with HIPEC in the treatment of advanced colorectal cancer patients did not significantly increase the incidence of common postoperative complications. However, the second-degree myelosuppression of advanced colorectal cancer patients who received 3 times of HIPEC during the perioperative period was significantly higher than that of 1~2 times. Meanwhile, clinicians should pay close attention to the incidence of adverse events in women or advanced colorectal cancer patients with low (or high) BMI undergoing radical resection combined with HIPEC treatment.

图1 研究队列
表1 不良事件评价(CTCAE v5.0)分级标准11
表2 123例局部进展期结直肠癌患者临床病理特征表[例(%)]
图2 123例局部进展期结直肠癌患者术后住院时间直方图
表3 123例局部进展期结直肠癌患者根治术后行HIPEC治疗围手术期不良事件统计表[例(%)]
表4 123例局部进展期结直肠癌患者围手术期不良事件logistics分析
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]
O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging[J]. J Natl Cancer Inst, 2004, 96 (19): 1420-1425.
[4]
Hompes D, Tiek J, Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?[J]. Ann Oncol, 2012, 23(12): 3123-3129.
[5]
egelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012, 99(5): 699-705.
[6]
Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique[J]. Ann Surg Oncol, 1999, 6(8): 790-796.
[7]
Razenberg LG, van Gestel YR, Creemers GJ, et al. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands[J]. Eur J Surg Oncol, 2015, 41(4): 466-471.
[8]
中国抗癌协会腹膜肿瘤专业委员会, 广东省抗癌协会肿瘤热疗专业委员会. 中国腹腔热灌注化疗技术临床应用专家共识(2019版)[J]. 中华医学杂志, 2020, 100(2): 89-96.
[9]
Bannay A, Chaignot C, Blotière PO, et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality[J]. Med Care, 2016, 54(2): 188-194.
[10]
Weiser MR. AJCC 8th edition: colorectal cancer[J]. Ann Surg Oncol, 2018, 25(6): 1454-1455.
[11]
NIH Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0[R]. 2017.
[12]
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[13]
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin[J]. J Clin Oncol, 2009, 27(5): 681-685.
[14]
Klaver CEL, Wisselink DD, Punt CJA, et al. COLOPEC collaborators group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(10): 761-770.
[15]
张日雄, 吴祖光, 李恩, 等. 进展期结直肠癌根治术后腹腔热灌注化疗联合全身化疗的临床相关性研究[J]. 岭南现代临床外科, 2017, 17(1): 39-42.
[16]
吴川清, 王点石, 李源, 等. 腹腔镜下结直肠癌根治术后早期腹腔热灌注化疗的安全性评价[J]. 中华普通外科杂志, 2020, 35(10): 810-811.
[17]
孙立峰, 丁克峰. 肿瘤细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)治疗结直肠癌腹膜转移的现状和进展[J/CD]. 中华结直肠疾病电子杂志, 2020, 9(2): 127-130.
[18]
Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
[19]
Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy[J]. Int J Hyperthermia, 2007, 23(5): 431-442.
[20]
Hornung M, Werner JM, Schlitt HJ. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer[J]. Expert Rev Anticancer Ther, 2017, 17(9): 841-850.
[21]
李晶,赵宝成,王振军. 加速康复外科理念下结直肠癌围手术期营养支持治疗[J]. 临床外科杂志, 2021, 29(7): 693-695.
[1] 张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性:单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 罗青杉, 梅海涛, 郝家领, 蔡锦锋, 周润楷, 温玉刚. 连接蛋白43通过调控细胞周期抑制结直肠癌的增殖机制研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 344-349.
[4] 朴成林, 蓝炘, 司振铎, 李强, 冯健, 安峰铎, 冷建军. 胰十二指肠切除联合肝切除术疗效分析:附5例报告(附视频)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 363-367.
[5] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[6] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[7] 王鹏, 邵欣欣, 胡海涛, 田艳涛, 钟宇新. 改良MOBS 吻合法在全腹腔镜近端胃大部分切除中的应用[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 267-270.
[8] 张瑜, 姜梦妮. 基于DWI信号值构建局部进展期胰腺癌放化疗生存获益预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 657-664.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[11] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[12] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[13] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[14] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[15] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
阅读次数
全文


摘要